Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WHSC1L2P (Wolf-Hirschhorn syndrome candidate 1-like 2, pseudogene) is a human pseudogene related by sequence homology to the functional histone methyltransferases WHSC1 (NSD2/MMSET) and possibly WHSC1L1 (NSD3), both of which are implicated in epigenetic regulation through histone methylation, cell differentiation, and oncogenesis[2][4]. However, WHSC1L2P itself lacks protein-coding capacity and functional characterization; there is no evidence it encodes an active histone methyltransferase or participates in signaling pathways or cellular processes. Accordingly, it is not considered a therapeutic target, receptor, enzyme, transporter, or biomarker, and there are neither known drugs nor clinical applications associated with it[2]. Its annotation and aliases reflect its sequence similarity and historical naming conventions, but scientific literature does not attribute any biological activities, disease roles, or therapeutic significance to this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Wolf-Hirschhorn syndrome candidate 1-like 2, pseudogene (WHSC1L2P).